RecruitingNot ApplicableNCT07112287
Germline Testing for Predisposition to Myeloid Malignancies
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
Sponsor
Christopher Reilly
Enrollment
200 participants
Start Date
Nov 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age of 18 years or older
- Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
- Ability to understand and provide a signed and completed consent document in English.
Exclusion Criteria2
- Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
- Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEMyeloGen Gene Panel
The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07112287
Related Trials
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT0450112012 locations
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
NCT061297342 locations
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
NCT057591431 location
A Telehealth Advance Care Planning Intervention
NCT058758051 location
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
NCT072630741 location